PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-postive Metastatic Breast Cancer.

Not yet recruiting

Conditions: Metastatic HER2+ Advanced Breast Cancer

Interventions: Drug: Tucatinib
Drug: Trastuzumab
Drug: Capecitabine

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06961331

A Study to Learn More About TIVDAK in Women With Cervical Cancer That Has Come Back

Phase 4

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: TIVDAK

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT06952660

Locations: 🇺🇸
Trials365, LLC, Shreveport, Louisiana, United States
🇺🇸
Willis Knighton Cancer Center, Shreveport, Louisiana, United States
🇺🇸
Willis Knighton Physician Network - Hematology/Oncology, Shreveport, Louisiana, United States

and more 3 locations

A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

Active, not recruiting

Conditions: COVID-19 SARS-CoV-2 Infection
COVID-19
COVID-19 Infection
Coronavirus Disease 2019 (COVID-19)
COVID-19 (Coronavirus Disease 2019)
COVID-19 Vaccination
COVID-19 Vaccines
SARS-CoV-2 Infection, COVID19
SARS-CoV-2 Infection, COVID-19

Interventions: Drug: BNT162b2

First Posted Date: 2025-04-11

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06923137

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: PF-07941944
Drug: Placebo
Drug: Midazolam

First Posted Date: 2025-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT06920498

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Drug: PF-07976016
Drug: PF-06882961

First Posted Date: 2025-04-04

Last Posted Date: 2025-05-04

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT06910839

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Vepdegestrant (Reference)
Drug: Vepdegestrant (Test)

First Posted Date: 2025-04-04

Last Posted Date: 2025-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06911788

Locations: 🇳🇱
ICON, Groningen, Netherlands
🇳🇱
ICON - screening centre, Utrecht, Netherlands

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruiting

Conditions: Atopic Dermatitis
Atopic Dermatitis, Unspecified
Dermatitis, Atopic

Interventions: Drug: Abrocitinib

First Posted Date: 2025-03-27

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT06899204

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Phase 1

Not yet recruiting

Conditions: Healthy Adults

Interventions: Drug: PF-07220060
Drug: Carbamazepine ER Tablet

First Posted Date: 2025-03-27

Last Posted Date: 2025-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT06897683

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

Consistency of Response With Rimegepant in Acute Treatment of Migraine

Not yet recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant for acute migraine treatment

First Posted Date: 2025-03-27

Last Posted Date: 2025-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT06898047

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Phase 3

Active, not recruiting

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Biological: HZ/su VACCINE

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 525

Registration Number: NCT06890416

Locations: 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
DelRicht Research, New Orleans, Louisiana, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy